The value of these services is reciprocal to the burden of disease and can be expressed in terms of reduction in the incidence (i.e., cases avoided), reduction in mortality (i.e.,

live years saved and quality-adjusted life years saved), and reduction in cost of illnesses. Often policy-makers tend to think that prevention is costly, as it needs funding here and now. Articles like Thein et al.’s provide evidence that failure to prevent can be even more costly: here, now, and in the future. Lorenzo G. Mantovani1Mario Strazzabosco2 “
“Hepatitis C virus (HCV) is a major cause of global morbidity, causing chronic liver injury that can progress to cirrhosis and hepatocellular carcinoma. The liver is a large and complex organ containing multiple cell types, including hepatocytes, sinusoidal endothelial cells (LSEC), Kupffer cells, and biliary epithelial cells. Hepatocytes are the major reservoir find more supporting HCV replication; however, the role of nonparenchymal cells in the viral lifecycle remains largely unexplored. LSEC secrete factors that promote HCV infection and transcript analysis identified bone morphogenetic protein 4 (BMP4) as a candidate endothelial-expressed proviral molecule. Recombinant BMP4 increased HCV replication BAY 57-1293 mw and neutralization of BMP4 abrogated the proviral activity of LSEC-conditioned media.

Importantly, BMP4 expression was negatively regulated by vascular medchemexpress endothelial growth factor A (VEGF-A) by way

of a VEGF receptor-2 (VEGFR-2) primed activation of p38 MAPK. Consistent with our in vitro observations, we demonstrate that in normal liver VEGFR-2 is activated and BMP4 expression is suppressed. In contrast, in chronic liver disease including HCV infection where there is marked endothelial cell proliferation, we observed reduced endothelial cell VEGFR-2 activation and a concomitant increase in BMP4 expression. Conclusion: These studies identify a role for LSEC and BMP4 in HCV infection and highlight BMP4 as a new therapeutic target for treating individuals with liver disease. (Hepatology 2014;59:375–384) “
“According to World Health Organization, in 2010 there were over 1 billion overweight adults worldwide with 400 million adults who were obese. Obesity is a major risk factor for diabetes, cardiovascular disease, musculoskeletal disorders, obstructive sleep apnea, and cancers (prostate, colorectal, endometrial, and breast). Obese people may present to the gastroenterologists with gastroesophageal reflux, non-alcoholic fatty liver, and gallstones. It is important, therefore, to recognize and treat obesity. The main cause of obesity is an imbalance between calories consumed and calories expended, although in a small number of cases, genetics and diseases such as hypothyroidism, Cushing’s disease, depression, and use of medications such as antidepressants and anticonvulsants are responsible for fat accumulation in the body.